
Sign up to save your podcasts
Or


Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.
By Axios4.3
689689 ratings
Axios Re:Cap is revisiting some of this year’s biggest stories and what they say about where technology, business, politics and more are headed in 2022.
Alison Snyder, managing editor and author of Axios Science, joins Axios Re:Cap senior producer Naomi Shavin to discuss a major research trend that flew under the radar this year: increased public and private funding for trials looking into therapeutic psychedelics.

32,100 Listeners

30,666 Listeners

8,776 Listeners

26,250 Listeners

111,948 Listeners

56,508 Listeners

10,282 Listeners

5,201 Listeners

6,089 Listeners

556 Listeners

5,485 Listeners

10,182 Listeners

6,381 Listeners

2,020 Listeners

5,530 Listeners

4,365 Listeners

15,950 Listeners